Nanobiotix shares surge 36.5% over one month and aim for their MM200
The Paris-based oncology nanomedicine biotech continues its recovery in early afternoon trading, in a rising market. The stock is approaching a technical zone it had left in October, while management prepares two meetings with the financial community in London.
A 14.5% rebound over seven days that brings the stock back above its short-term averages
Nanobiotix gains 1.68% to €28.98 after rising 14.45% over the week and 36.44% over one month. Over three months, the performance remains negative at -13.39%, so the October rebound softens this decline without erasing it.
The share price stands 13.42% above its MM20 at €25.55 and 7.10% above its MM50 at €27.06, but it remains 2.03% below the MM200 at €29.58, the last medium-term barrier to clear.
Meanwhile, the RSI at 59 remains neutral: the rise has not yet pushed the indicator into overbought territory. In the SBF 120, which gains 1.12% intraday, the stock is outperforming the index but does not rank among the day's biggest gainers.
Jefferies and UBS conferences on November 16 and 17 in London, then cash runway until 2029
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In a press release published on November 9, Nanobiotix stated that it would present its work at the Jefferies and UBS conferences held in London on November 16 and 17. This agenda item alone does not change the outlook for the development of JNJ-1900 (NBTXR3), conducted with Johnson & Johnson.
When it published its first-half 2026 results on September 24, the company reported cash of €110.9 million, sufficient to fund its operations until 2029.
The share price is now approaching its €30.36 resistance level, close to where it traded at the end of October, while the MM200 at €29.58 sits just above the share price.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
